Krsnaa Diagnostics Q2 FY27 slides: record revenue, margin pressure

Krsnaa Diagnostics reported record Q2 FY27 revenue of INR 2,710 million, up 32% year over year, but EBITDA rose only 20% to INR 719 million and its margin contracted 200 basis points to 27%; PAT increased 3% to INR 246 million as PAT margin fell to 9% from 12%. H1 FY27 PAT declined 8% to INR 411 million, while tests performed grew 85% to 30.3 million. Management expects to collect approximately INR 2,000 million in receivables in Q3 and says the Rajasthan pathology PPP project could reach an annualized revenue run rate of INR 2,500 million, with most benefits expected in FY28. Shares fell 3.72% to $480.15, near the reported 52-week low of $463.10, amid concerns about expansion costs and near-term profitability.

Analysis

Krsnaa’s key underwriting question is cash conversion, not demand. PPP scale can add volume while weakening economics if fixed costs arrive before utilization and state receivables lag; the resulting working-capital draw can absorb the operating leverage investors are waiting for. The sharp rise in payables may temporarily cushion that draw, but if it reflects delayed settlement rather than ordinary project timing, suppliers could become an indirect source of financing and constrain execution. Treat management’s Q3 collection expectation as a near-term proof point, not cash until it appears in reported balances.

Retail growth is not yet evidence of attractive unit economics: lower revenue per patient alongside faster patient growth is consistent with an affordability-led mix, which may help acquisition but could extend the path to durable profitability. That also puts Krsnaa in direct competition with established organized providers such as Dr Lal PathLabs, Metropolis Healthcare and Thyrocare for private-pay customers; winning share through price would weaken the strategic value of retail scale.

Near term (days to weeks), the cautious reaction is understandable; there is no clean earnings-quality catalyst until collections and margins are demonstrated. Over 1–3 months, realized receivable reduction and retail break-even are the tests. Over 6–18 months, Rajasthan utilization could create operating leverage, but the payoff depends on contract economics and timely government payments. Contrarian angle: the market may be discounting the ramp before utilization matures, but that is not yet a reason to buy—guidance is not proof of cash generation. Thesis weakens materially if Q3 collections miss, receivables remain elevated, or margins fail to stabilize as new centers mature.

Key Decisions for Investors

• Do not chase revenue growth alone. Keep Krsnaa Diagnostics on a results-watch list and require reported Q3 cash collection / receivables improvement before adding exposure; verify whether the expected collections are actually received rather than merely invoiced or acknowledged.
• Use margin and working-capital milestones as the trade trigger: a receivables decline alongside stable or improving EBITDA margin would support a staged long; continued margin compression or no meaningful receivables relief would argue to stay underweight. No price target is warranted without valuation and consensus data.
• For relative exposure, consider favoring established organized diagnostics operators such as Dr Lal PathLabs, Metropolis Healthcare or Thyrocare over Krsnaa if private-pay competition intensifies or Krsnaa’s retail growth requires sustained affordability-led pricing. This is a conditional quality/cash-conversion view, not a claim about their current relative valuation.
• Falsifiers to monitor over the next 1–3 months: Q3 cash collections materially below management’s stated expectation, further deterioration in receivables or supplier payments, retail failing to reach the stated break-even window, or margins not recovering as Rajasthan utilization ramps. Reassess the structural growth thesis if these persist into subsequent reporting periods.